The impact of crystallization conditions on structure-based drug design: a case study on the methylene blue/acetylcholinesterase complex

Orly Dym(Weizmann Institute of Science), Israel Silman(Weizmann Institute of Science), Robbie P. Joosten(Oncode Institute), Wanling Song(Guizhou Institute of Technology), Joel L. Sussman(Weizmann Institute of Science), Valery L. Shnyrov(Universidad de Salamanca), Clifford E. Felder(Weizmann Institute of Science), Yechun Xu, Esther Roth(Weizmann Institute of Science), Lev Weiner, Yacov Ashani(Weizmann Institute of Science)
DORA PSI (Paul Scherrer Institute)
January 1, 2016
Cited by 0

Related Papers

The<i>PDB_REDO</i>server for macromolecular structure model optimization
|IUCrJ|2014|898
The <i>CCP</i>4 suite: integrative software for macromolecular crystallography
|Acta Crystallographica Section D Structural Biology|2023|852
AlphaFill: enriching AlphaFold models with ligands and cofactors
|Nature Methods|2022|498
A New Generation of Crystallographic Validation Tools for the Protein Data Bank
|Structure|2011|475
PtdIns(4,5)P2 stabilizes active states of GPCRs and enhances selectivity of G-protein coupling
|Nature|2018|317